Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News
Stock Performance & Recent Market Reaction Intensity Therapeutics shares were flat-to-down during Oct. 2025 until the news, trading around $0.27 on Oct. 29 ts2.tech. On Oct. 30 (Thursday), publication of its trial in Lancet sent the stock parabolic: intraday it soared nearly 395%, closing at $1.32 benzinga.com. In after-hours trading, the stock gave up much of the gain and traded around $0.90 by the end of Thursday benzinga.com. (Benzinga reported a 31.9% after-hours decline benzinga.com.) A massive volume surge accompanied the move – hundreds of millions of shares changed hands (compared to ~5 million normally) ts2.tech. Despite this spike, INTS